Literature DB >> 8225622

Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy.

J Blaser1, B Joos, M Opravil, R Lüthy.   

Abstract

Serum kinetics of trimethoprim and sulfamethoxazole were studied in 23 patients during oral and i.v. treatment of Pneumocystis carinii pneumonia. Daily doses of 15-22 mg/kg trimethoprim and 75-110 mg/kg sulfamethoxazole were given every 6 h. Despite administration of a loading dose of twice the regular dose, serum trough concentrations continuously rose from 12 h to 96 h by 63% for trimethoprim and 102% for sulfamethoxazole. After 4-6 days mean trough concentrations of trimethoprim and sulfamethoxazole were 7.7 +/- 3.0 and 198 +/- 74 mg/l, with individual values of < 4.6 and < 103 mg/l in two patients and > 11.4 and > 307 mg/l in two others. Patients treated orally or i.v. had similar serum levels. However, large interindividual variability was observed despite weight-specific dosing. Administration of a loading dose did not prevent accumulation of serum levels of trimethoprim and sulfamethoxazole over several days of treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225622     DOI: 10.1007/bf01728888

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

Review 1.  Adverse reactions to co-trimoxazole in HIV infection.

Authors:  A J van der Ven; P P Koopmans; T B Vree; J W van der Meer
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

2.  Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg).

Authors:  R J Fass; R B Prior; R L Perkins
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

3.  Modified trimethoprim-sulphamethoxazole doses in Pneumocystis carinii pneumonia.

Authors:  I McLean; C R Lucas; M L Mashford; P J Harman
Journal:  Lancet       Date:  1987-10-10       Impact factor: 79.321

4.  Serum trimethoprim and sulphamethoxazole levels in AIDS.

Authors:  F J Bowden; P J Harman; C R Lucas
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

Review 5.  Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.

Authors:  A E Glatt; K Chirgwin
Journal:  Arch Intern Med       Date:  1990-02

Review 6.  Pneumocystis carinii pneumonia: therapy and prophylaxis.

Authors:  J A Kovacs; H Masur
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

7.  Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial.

Authors:  N C Klein; F P Duncanson; T H Lenox; C Forszpaniak; C B Sherer; H Quentzel; M Nunez; M Suarez; O Kawwaff; A Pitta-Alvarez
Journal:  AIDS       Date:  1992-03       Impact factor: 4.177

8.  Can the course of high dose cotrimoxazole for Pneumocystis carinii pneumonia in AIDS be shorter? A possible solution to the problem of cotrimoxazole toxicity.

Authors:  J K Eeftinck Schattenkerk; J M Lange; R P van Steenwijk; S A Danner
Journal:  J Intern Med       Date:  1990-05       Impact factor: 8.989

9.  Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects.

Authors:  R C Stevens; S C Laizure; C L Williams; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia.

Authors:  D J Winston; W K Lau; R P Gale; L S Young
Journal:  Ann Intern Med       Date:  1980-06       Impact factor: 25.391

View more
  9 in total

1.  Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents.

Authors:  K W Henry; M C Cruz; S K Katiyar; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia.

Authors:  F Sesti; G W Abbott; J Wei; K T Murray; S Saksena; P J Schwartz; S G Priori; D M Roden; A L George; S A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

3.  Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients.

Authors:  T W Chin; A Vandenbroucke; I W Fong
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia.

Authors:  B Joos; J Blaser; M Opravil; J P Chave; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

5.  Serum peak sulfamethoxazole concentrations demonstrate difficulty in achieving a target range: a retrospective cohort study.

Authors:  Bao D Dao; Jason N Barreto; Robert C Wolf; Ross A Dierkhising; Matthew F Plevak; Pritish K Tosh
Journal:  Curr Ther Res Clin Exp       Date:  2014-11-11

Review 6.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440

7.  Observational study of the clinical utility of sulfamethoxazole serum level monitoring in the treatment of brain abscesses due to Nocardia species.

Authors:  Cristina Corsini Campioli; Omar Abu Saleh; Kristin C Mara; Christina G Rivera
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

8.  Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.

Authors:  E Zielińska; W Niewiarowski; J Bodalski; G Rebowski; J Skretkowicz; K Mianowska; M Sekulska
Journal:  Pharm World Sci       Date:  1998-06

Review 9.  Cotrimoxazole - optimal dosing in the critically ill.

Authors:  Glen R Brown
Journal:  Ann Intensive Care       Date:  2014-04-28       Impact factor: 6.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.